U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07566091) titled 'Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers' on April 27.
Brief Summary: The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clini...